Apr. 15 at 7:19 PM
$SLS Buyout Price Target
$180 ... Mark this Post.
Gps Immunotherapy will treat upwards of 50,000 AML Remission Patients Each Year.
$280K Rev Per Patient, Compounded, indefinite dosing regime until relapse for patients surviving +5 years.
$ABVX was a
$5 Stock, bounced around, had doubled to
$10 - when its Phase 3 Trial Results were announced, and halted trading.
T1 Trading Halt +600% GAP Up to
$60
and it Kept climbing to a high of
$148 ...
$RVMD just added
$10B in Value on its P3 Data.
Something Similar is about to happen here.
